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Introduction
Elevated plasma levels of free fatty acids (FFA) are thought to play a major role in the pathogenesis of insulin resistance and type 2 diabetes (Frayn, 2002; Unger, 1995; Boden, 1997) by inhibiting glucose uptake and utilization by muscle (Kim et al, 2001) and causing increased glucose output by the liver (Large and Arner, 1998) . These events combine to produce the hyperglycemia that is characteristic of type 2 diabetes (Groop et al, 1991) . The increase in plasma FFA levels are the result of increased mobilization from adipose tissue. Hormone-sensitive lipase (HSL), thought to be the rate-limiting enzyme in adipose tissue lipolysis, hydrolyzes the stored trigylcerides into monoglycerides and FFA (Large and Arner, 1998) .
The activity of HSL is acutely activated via cAMP and protein kinase A mediated phosphorylation (Anthonsen et al, 1998) in response to epinephrine/norepinephrine.
Insulin stimulation of adipocytes prevents HSL activation, leading to a decrease in the release of FFA and glycerol (Langin et al, 1996) . The role of elevated plasma FFA in type 2 diabetes has led to the proposal that HSL may be a potential therapeutic target for this disease, lowering plasma FFA levels and thereby reducing insulin resistance. Results with HSL knockout mice, however, have raised the question of whether it is a suitable target. Conflicting effects on both insulin sensitivity (Osuga et al, 2000; Okazaki et al, 2002; Saltiel, 2000; Haemmerle et al, 2002; Voshol et al, 2003) and insulin secretion (Roduit et al, 2001; Mulder et al, 2003) have been reported. Small-molecule HSL inhibitors have recently been identified (Vertesy et al, 2002; Slee et al, 2003; Lowe et al, 2004; Ebdrup et al, 2004; De Jong et al, 2004) . Here, we This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on September 14, 2005 as DOI: 10.1124 at ASPET Journals on July 7, 2017 jpet.aspetjournals.org Downloaded from describe a highly potent, reversible, and selective inhibitor, and use it to clarify the effects of HSL inhibition in isolated adipocytes and on the levels of glycerol, FFA, and glucose in mouse, rat and dog.
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Synthesis of HSL Inhibitor:
Chemically, BAY (Figure 1 ) is a (5-(2H)-isoxazolonyl urea, produced as a low-melting crystalline solid. The parent heterocycle is synthesized from the substituted acetoacetate ester, followed by acylation and urea formation. Details of the synthesis and the structure-activity relationships of a variety of similar isoxazolone HSL inhibitors are detailed in a separate publication (Lowe et al, 2004) . Column samples were kept on ice. The Post-Column samples were applied to a G25 spin column to remove compound. The Column + Compound were applied to a spin column to remove compound, then compound was added back to a final concentration of 10 µM. All samples were then assayed for hormone-sensitive lipase activity as described above. Results are expressed as average A 550 +/-SD.
In vitro Enzyme
Adipocyte lipolysis: Lipolysis was measured in either 3T3-L1 cells differentiated for 8 days (Fong, 1990) , in freshly isolated rat adipocytes prepared as described (Rodbell, 1964) The animals were fed ad libitum until the day before the experiment when the food was removed overnight (16-18 hour fast). Male beagle dogs from the in-house colony were also fasted overnight. Male Sprague-Dawley rats (Charles River Laboratories) were made diabetic by tail vein injection of 45 mg/kg streptozotocin in citrate buffer, pH 4.0.
One week later, they were fasted for 5 hours prior to the experiment.
This article has not been copyedited and formatted. The final version may differ from this version. In Vivo Testing: Overnight fasted Balb/C mice and Wistar rats were given an oral dose of 30 mg/kg BAY or 0.5% methylcellulose. Blood was collected by retro-orbital puncture just prior to dosing and again at 0.5, 1, 1.5 and 2 hours after dosing the mice.
Blood was collected from rats by tail vein clip prior to dosing and at 1, 2, and 3 hours after dosing. The streptozotocin diabetic rats were tail bled after 3 hours. The dogs were
given BAY or PEG 400/propylene glycol (80:20) via oral gavage. A blood sample was withdrawn from a cephalic vein just prior to dosing and after 1, 2, 4 and 6 hours. The same dogs were used for both the vehicle and BAY treatments, which were done one week apart from each other. Plasma was analyzed for free fatty acid and glycerol concentration using a NEFA kit and the Triglyceride (TPO-Grinder) kit, respectively.
Statistics:
The results are expressed as mean ± SEM. Intergroup comparisons were performed by unpaired Student's t test or by ANOVA with Dunnett's t test for multiple comparisons, where appropriate. P<0.05 was considered significant.
Insulin secretion from rat islets:
Rat pancreatic islets were isolated as follows. Briefly, the rat is anesthetized with 0.2 ml Nembutal/100 g body weight. minutes. The media was removed for the determination of insulin using the 1-2-3 Rat
Insulin EIA kit. 
RESULTS

In vitro
In vivo inhibition of lipolysis:
The effect of BAY on plasma free fatty acid and glycerol levels were determined in mice, rats and dogs following an overnight fast to stimulate lipolysis ( Figure 5 ). BAY reduced plasma glycerol levels by 50% in all three species.
However, BAY caused a much greater reduction in plasma free fatty acid levels in dogs (70%) than in mice (25%), and had no significant effect in rats. An equivalent dose of acipimox, a niacin derivative used to reduce plasma lipids through inhibition of lipolysis, reduced plasma glycerol levels in rats to the same extent as BAY, but it was less effective than BAY in mice (25% vs 50%). In contrast to BAY, acipimox inhibited free fatty acid levels by 90% in rats, while in mice it was less effective than was BAY.
Ex vivo inhibition of lipolysis:
Following treatment of normal rats with BAY, plasma glycerol ( Figure 6A ) remained suppressed after 8 h despite the absence of measurable concentrations of BAY in plasma ( Figure 6B) . In order to determine whether the sustained suppression of glycerol levels could be attributed to inhibition of adipocyte lipolysis or was due to off target effects of the compound, animals were treated and the rate of lipolysis determined at several time points. The inhibitory effect of BAY was still observed as a blunted forskolin response in omental fat removed at 4 and 8 h ( Figure   6C ). Thus, the in vitro BAY-induced suppression of lipolysis in the presence of forskolin This article has not been copyedited and formatted. The final version may differ from this version. Effect of acipimox and BAY in streptozotocin diabetic rats: It has been reported previously that acipimox lowers plasma glycerol and FFA in STZ rats, resulting in a decrease in plasma glucose. The effects of BAY and acipimox were compared in streptozotocin-induced diabetic rats 3 hours after a single dose (Figure 7) . Both compounds lowered plasma glucose and glycerol levels, with acipimox showing a trend toward greater reduction than BAY. Acipimox significantly reduced free fatty acid levels, while the reduction of free fatty acids by BAY was not significant. Neither compound had any significant effect on weight gain.
Effects on insulin secretion:
The changes observed in plasma glucose in response to BAY could be due to effects on insulin sensitivity or on insulin secretion. Changes in insulin secretion have been reported in animals lacking HSL. To determine if treatment with BAY reproduced these effects, islets were isolated from rat pancreas and insulin secretion measured following treatment with various agents in the presence or absence of BAY.
This article has not been copyedited and formatted. The final version may differ from this version. BAY had no effect on arginine or on agents acting directly on the potassium channel, such as glybenclamide. Taken together, the data supports a role for HSL in the enhancement of glucose-dependent insulin secretion, but not in actual nutrient sensing.
Under no conditions did inhibition of HSL by BAY cause an enhancement of insulin secretion. The glucose lowering effects of BAY must, therefore, be due to effects on insulin sensitivity rather than insulin secretion.
This article has not been copyedited and formatted. The final version may differ from this version. (Osuga et al, 2000; Okazaki et al, 2002; Saltiel, 2000) , and with basal lipolysis being carried out by an enzyme distinct from HSL. Together, our results support the suggestion that another lipase with similar functionality is present in adipose tissue (Osuga et al, 2000; Okazaki et al, 2002; Saltiel, 2000) . The accumulation of diglycerides in adipose tissue of HSL knockout mice (Haemmerle et al, 2002) suggests that both HSL and a putative lipase are able to hydrolyze triacylglycerol, but only HSL is capable of hydrolyzing diacylglycerol. The recently identified adipose triglyceride lipase has been proposed as a candidate for this non-HSL lipolytic activity, and selective HSL inhibitors may provide useful tools to further clarify its role (Zimmerman et al, 2004) .
We examined the effects of BAY in vivo on plasma levels of glycerol and FFA.
BAY reduced plasma levels of glycerol to the same extent in mice, rats and dogs, but the effects on plasma FFA levels were species dependent with BAY being more effective in This article has not been copyedited and formatted. The final version may differ from this version. dogs than in mice, and with no significant effect in rats. The results suggest that HSL is the major, if not the only, lipase involved in lipolysis in dogs. In rats, the inhibition of HSL-mediated lipolysis is sufficient to prevent the release of glycerol into the circulation, but not to prevent the release of FFA. This is consistent with the finding in knockout mice that HSL is critical for diacylglycerol but not triacylglycerol hydrolysis (Haemmerle et al, 2002) . Acipimox had a similar effect on plasma glycerol, but a much greater effect on plasma FFA levels than BAY in rats. Acipimox exerts its anti-lipolytic effects through a G-protein coupled receptor, HM74A (Tunaru et al, 2003) , which suggests that activation of HM74A in rats leads to modulation of the activities of lipolytic enzymes other than HSL, thereby having a greater effect on lipolysis than can be accomplished solely through direct inhibition of HSL.
Initial studies on the effect of decreased plasma FFA levels on plasma glucose were carried out with acipimox and nicotinic acid. Treatment of STZ diabetic rats with these agents resulted in a dramatic decrease in FFA and a significant decrease in plasma glucose (Reaven et al, 1988) . In the present study, BAY signifiantly decreased plasma glycerol without a statistically significant change in FFA, and these changes were accompanied by a small, but significant, decrease in plasma glucose levels in the STZ rats. The fact that acipimox had greater effects on plasma FFA, glycerol, and glucose is consistent with the suggestion that this drug effects FFA and glycerol release through mechanisms in addition to HSL inhibition.
Plasma glucose lowering can be achieved either through improvements in insulin sensitivity or enhanced insulin secretion. To better understand the mechanism of glucose lowering, we studied the effects of BAY on insulin secretion. pancreatic β-cells has been confirmed in isolated islets from rodents (Mulder et al, 1999) , as well as several β-cell lines at levels of mRNA, protein or enzyme activity. It is generally agreed that HSL plays an important role in the lipid metabolism of pancreatic β-cells. However, whether HSL is essential for insulin release stimulated by nutrients and various secretagogues is still under investigation.
The role of HSL in insulin secretion has been studied mostly through the use of knockout mice. It has been reported that there was a defect in insulin secretion in HSL null mice (Roduit et al, 2001 ), while another study observed an intact insulin release of pancreatic islets isolated from HSL null mice (Mulder et al, 2003) . Whether HSL participate the mechanism of glucagon-like peptide 1 (GLP-1) insulinotropic effect is also an uncertain issue. GLP-1 enhances insulin release via increasing cAMP and PKA pathway, which activate HSL. It has been reported that GLP-1 stimulates lipolysis in clonal pancreatic beta-cells (HIT). The GLP-1 induced lipolysis might have a positive impact on insulin release via lipid signaling, since lipase inhibition with orlistat substantially reduced the effect on GLP-1 on insulin release from islets of SpragueDawley rats (Cunningham et al, 2003) . Orlistat also inhibited forskolin-stimulated insulin release from rat islets (Mulder et al, 2004) . However, GLP-1 appears to have no effect on mouse islet lipolysis and GLP-1 stimulated insulin release was intact in isolated islets from HSL null mice (Peyot et al, 2004) , suggesting that HSL might not participate the mechanism of GLP-1 insulinotropic effect, at least in mouse islets. Whether these controversial observations may be explained by differences among animal species is yet unknown.
This article has not been copyedited and formatted. The final version may differ from this version. In the present study, we observed that BAY inhibited insulin release in response to secretagogues acting through the cAMP pathway, such as glucagon-like peptide 1 and forskolin. Interestingly, BAY also inhibited the protein kinase C pathway at a point prior to activation of protein kinase C, as it was able to block responses to acetylcholine, but not to phorbol 12,13-dibutyrate. BAY also showed no effect on stimulation of insulin secretion by glucose or arginine, or in response to activation of K ATP channel by sulfonylureas. Thus, BAY's inhibitory effect on GLP-1 and acetylcholine warrant further investigation. Considering that there might be other lipases in pancreatic β-cells that might be involved in lipid signaling of insulin release, studies on the effect of BAY on islet lipolysis need to be conducted to confirm that the effect of BAY on insulin release is due to inhibition of HSL mediated lipolysis. Furthermore, it has been reported that overexpression of HSL induce pancreatic β-cell lipotoxicity (Winzell et al, 2003) . Exploring whether HSL activity in increased in diabetic pancreatic islets will help in evaluating the therapeutic potential of HSL inhibitors for type 2 diabetes. Overall, our insulin release data indicate that BAY has no insulinotropic effect, but rather an inhibitory effect on insulin secretion from isolated rat islets in response to certain secretagogues. These data support the hypothesis that BAY lowers plasma glucose through improving insulin sensitivity, not via insulin secretion.
In summary, our data support a connection between adipose tissue lipolysis and plasma glucose levels (Saloranta and Groop, 1996; Boden, 1999) in agreement with the hypothesis that decreased plasma FFA lead to improved insulin sensitivity. However, as both glycerol and glucose were significantly decreased by BAY in the STZ rat, while FFA were not, glucose may correlate more closely with plasma glycerol than FFA levels. The rats were treated with vehicle ( ), BAY ( ), or acipimox ( ) as described under Methods, and plasma glycerol (A), fatty acids (B), and glucose (C) were determined.
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